ML281

Research use only, not for human use.

ML281 is a potent and selective STK33 inhibitor with IC50 of 14 nM.

ML-281 is a potent ans selective STK33 inhibitor (IC50 = 14 nM). ML281 showed low nanomolar inhibition of purified recombinant STK33 and a distinct selectivity profile as compared to other STK33 inhibitors. ML281 is a valuable addition to small-molecule probes of STK33. v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) is the most mutated oncogene, and KRAS mutations have been found in up to 20% of all human tumors. STK33 was selectively toxic to KRAS-dependent cancer cell lines, suggesting that small-molecule inhibitors of STK33 might selectively target KRAS-dependent cancers.

ML-281; ML-281; ML281

Others

Other Targets

STK33

Cancer

——

1404437-62-2

389.47

C22H19N3O2S

98%

DMSO : ≥ 30 mg/mL. 77.03 mM; H2O : < 0.1 mg/mL

O=C(c1cccs1)Nc1ccc(C(C)C)cc1c1nc2c(cccc2)[nH]c1=O

N-[2-(3,4-Dihydro-3-oxo-2-quinoxalinyl)-4-(1-methylethyl)phenyl]-2-thiophenecarboxamide

(-20℃)

With Ice Pack

≥ 2 years